Clinical and molecular characteristics of the CLL cohort
| Variable . | No. (%) . |
|---|---|
| Patients | 248 |
| Median age at diagnosis, y | 65.7 |
| Sex, male | 143 (58) |
| Binet stage at diagnosis, n = 244 | |
| A | 172 (71) |
| B | 49 (20) |
| C | 23 (9) |
| CD38, n = 245 | |
| 30% or more | 102 (42) |
| ZAP-70, n = 190 | |
| 20% or more | 59 (31) |
| IgV gene mutation status, n = 236 | |
| UM, less than 2% | 87 (37) |
| Genomic aberrations, n = 212 | |
| Deletion 11 | 15 (7) |
| Deletion 17 | 28 (13) |
| Deletion 13 | 103 (49) |
| Trisomy 12 | 44 (21) |
| Normal | 58 (27) |
| CD38 genotype, n = 248 | |
| CC | 153 (62) |
| GC | 86 (34) |
| GG | 9 (4) |
| CD38 allele frequency, n = 248 | |
| C | 0.79 |
| G | 0.21 |
| Variable . | No. (%) . |
|---|---|
| Patients | 248 |
| Median age at diagnosis, y | 65.7 |
| Sex, male | 143 (58) |
| Binet stage at diagnosis, n = 244 | |
| A | 172 (71) |
| B | 49 (20) |
| C | 23 (9) |
| CD38, n = 245 | |
| 30% or more | 102 (42) |
| ZAP-70, n = 190 | |
| 20% or more | 59 (31) |
| IgV gene mutation status, n = 236 | |
| UM, less than 2% | 87 (37) |
| Genomic aberrations, n = 212 | |
| Deletion 11 | 15 (7) |
| Deletion 17 | 28 (13) |
| Deletion 13 | 103 (49) |
| Trisomy 12 | 44 (21) |
| Normal | 58 (27) |
| CD38 genotype, n = 248 | |
| CC | 153 (62) |
| GC | 86 (34) |
| GG | 9 (4) |
| CD38 allele frequency, n = 248 | |
| C | 0.79 |
| G | 0.21 |
Percentages refer to total number of events scored.
UM indicates unmutated.